Resverlogix (RVX) Stock Price, News & Analysis

Company Overview

Founded in 2001, Resverlogix is a Calgary based late-stage biotechnology company, and a world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease. Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. We aim to improve patients' lives by restoring biological functions - altered by serious illnesses such as cardiovascular disease - back to a healthier state. The Company's clinical program is focused on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post COVID-19 conditions.

Key Stats

• Today's Range: C$0.09 to C$0.09
• 50-Day Range: C$0.09 to C$0.11
• 52-Week Range: C$0.08 to C$0.15
• Volume: 30,256 shs
• Average Volume: 33,092 shs
• Market Capitalization: C$29.26 million
• P/E Ratio: N/A
• Dividend Yield: 7.02%
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 11/12/2024
• Today: 10/14/2026

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: TSE:RVX
• CIK: N/A
• Web: www.resverlogix.com
• Phone: +1-403-2549252
• Fax: N/A
• Employees: 19
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): C($0.04)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -C$2.81 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: 10.92%
• Return on Assets: -34.90%

Debt

• Debt-to-Equity Ratio: -82.47
• Current Ratio: 0.04
• Quick Ratio: 0.04

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: C$0.00 per share
• Price / Cash Flow: 132.50
• Book Value: C($0.29) per share
• Price / Book: -0.30

Miscellaneous

• Outstanding Shares: 344,287,000
• Free Float: N/A
• Market Cap: C$29.26 million
• Optionable: Not Optionable
• Beta: -0.11